An Australian company committed to improving mental health outcomes.   

Therapeutics Goods Administration Makes History

 

Since 1 July 2023, specific psychedelics can be prescribed by approved authorised psychiatrists for the treatment of certain mental health conditions.  

   

The Therapeutic Goods Administration (TGA) have permitted the prescribing of the specific psychedelics for the treatment of post-traumatic stress disorder and for treatment-resistant depression. These are the only conditions where there is currently sufficient evidence for potential benefits in certain patients.   

  

Changes made by TGA represent a significant milestone for Australia's medical industry. It gives hope to individuals seeking treatment for their mental health conditions and opens opportunities for further research and development of psychedelic medicines.   

  

Based on these changes, Cortexa, an Australian company based in Melbourne, will be one of the only companies in the world able to supply the approved psychedelics ready for patient use.